You’re Wearing a WHOOP. Here’s What It Can’t Tell You.

Wearables have made us the most data-rich generation of patients in history. We know more about our sleep, our recovery, and our heart rate variability than any generation before us. And yet the markers that most reliably predict cardiovascular disease, metabolic decline, and early mortality do not appear on any wearable dashboard.

Lp(a). Insulin resistance. ApoB. hsCRP. These are not metrics that any consumer device currently measures — or can measure. They require a blood sample, a laboratory, and a clinician who knows what to do with the results.

This article is about the gap between what wearables track and what clinical screening measures — and why both, used together, give you something neither can provide alone.

What do wearables actually measure well?

First: wearables are useful. We want to be direct about this because dismissing them would be inaccurate and unhelpful. WHOOP, Oura Ring, Garmin, Apple Watch — these devices have improved substantially in the past five years, and several of the signals they track have genuine clinical relevance.

In Singapore, standard health screens — including Screen for Life — do not include the advanced blood markers (Lp(a), ApoB, HOMA-IR, hsCRP) or clinical fitness assessments (VO2 max, DEXA) that longevity medicine considers essential. Wearables fill part of this gap, but only part.

Devices covered in this article

HRV in particular is a signal we take seriously. It reflects autonomic nervous system balance — the interplay between your sympathetic (stress response) and parasympathetic (recovery) systems. Chronically low or declining HRV, tracked over months, is worth a clinical conversation. It may reflect overtraining, poor sleep quality, chronic stress, or early metabolic dysfunction.

Resting heart rate trends matter too. A gradual rise in resting heart rate over 12 months — even within a “normal” range — can signal declining cardiovascular fitness, increasing sympathetic tone, or the early stages of a metabolic shift that hasn’t yet shown up in a blood test.

This is the distinction that matters. HRV, sleep quality, resting heart rate — these are outputs. They reflect what is happening in your physiology. But they don’t tell you why. And the why — the upstream biology — is where clinical longevity medicine operates.

What can’t your wearable see?

Your wearable cannot measure what is happening in your blood. It cannot see your lipid particle architecture, your insulin sensitivity, your inflammatory load, your hormonal trajectory, or your cardiovascular risk markers. These require a blood draw and clinical analysis — and they are the markers that determine your long-term health trajectory most reliably.

Can your wearable really measure VO2 max?

This one deserves specific attention because it comes up constantly. Garmin, Apple Watch, and Polar all estimate VO2 max — and many patients who train seriously have a number in their head from their device and treat it as established fact.

Wearable VO2 max estimates work by modelling the relationship between your heart rate and your pace or power output during exercise, then extrapolating to what your maximum oxygen consumption would theoretically be. These algorithms have improved considerably and can be useful for tracking your own trends over time.

What they are not is a clinical assessment. Wearable estimates are not validated against the same population norms used in clinical research. They are sensitive to conditions — temperature, terrain, how tired you are, whether you took caffeine. They tend to be most accurate in steady-state outdoor running and least accurate in gym-based or interval training contexts.

More importantly: the mortality data linking low VO2 max to adverse health outcomes was generated using clinical protocols — treadmill or cycle ergometer tests in controlled conditions — not wearable estimates. Using a wearable number to assess clinical cardiovascular risk is making an inference the research does not support.

Why does HRV matter — and what can’t it diagnose?

HRV is probably the most clinically interesting signal that consumer wearables track. Heart rate variability — the beat-to-beat variation in the time between heartbeats — reflects autonomic nervous system balance, and lower HRV is associated in research with higher cardiovascular risk, poorer recovery, and greater physiological stress load.

The problem is that a low HRV reading from your WHOOP could reflect many things: a hard training week, poor sleep, alcohol, emotional stress, early infection — or something more significant like early metabolic dysfunction, insulin resistance, or subclinical inflammation. The wearable can detect the signal. It cannot identify the cause.

We have seen patients with chronically suppressed HRV who, on clinical investigation, had significant insulin resistance that had never been detected on a standard health screen. The wearable gave them a number. The blood test told them what was driving it.

Should you choose between wearables and clinical testing?

This is not an argument for abandoning your wearable. The point is the opposite.

Wearable data and clinical longevity screening are not competing. They operate on different timescales and measure different things. Your WHOOP gives you 365 days per year of physiological signal — granular, continuous, and responsive to your daily choices. A clinical longevity screen gives you biological depth once a year — the blood-based markers and functional assessments that determine your long-term trajectory.

Together, they give a more complete picture than either provides alone. Your wearable tells you your HRV has been suppressed for three weeks. Your blood test tells you your hsCRP is elevated and your insulin resistance has worsened — and that’s likely why. Now you have a mechanism, not just a signal. And with a mechanism, you have a target.

The most engaged patients we see in longevity medicine are the ones who already track. They understand data. They are motivated by numbers. They are already asking the right questions — they just don’t yet have access to the right layer of answers. That layer is what clinical testing provides.

What should you do with this information?

If you wear a fitness tracker and have never had a comprehensive blood panel beyond a standard health screen, the practical next step is straightforward. Get the markers your wearable cannot see:

• Lipoprotein(a) — genetically inherited cardiovascular risk factor. Tested once in a lifetime. Your wearable has no visibility of this whatsoever.
• ApoB and fasting insulin — vascular and metabolic markers absent from standard health screens. More predictive than total cholesterol or fasting glucose alone.
• hsCRP — chronic low-grade inflammation. May explain a persistently suppressed HRV that training adjustments haven’t resolved.
• Hormonal panel — testosterone, oestradiol, thyroid, DHEAS. Hormonal changes affect HRV, sleep quality, and recovery in ways that wearables detect as output but cannot trace to source.
• Clinical VO2 max assessment — validates or contextualises what your device has been estimating, and maps your fitness onto the clinical evidence base for longevity.

Bring your wearable data to the consultation. Trends in HRV, resting heart rate, and sleep quality over six to twelve months are genuinely useful clinical context. The doctor who understands both layers — what your device has been tracking and what the blood work shows — can give you a much more complete picture than either source alone.